CD155 as a therapeutic target in alveolar echinococcosis: insights from an Echinococcus multilocularis infection mouse model

IntroductionAlveolar echinococcosis (AE) is a life-threatening zoonotic parasitic disease caused by the metacestode stage of Echinococcus multilocularis, characterized by granulomatous lesions and liver fibrosis. Immune exhaustion is the key mechanism by which E. multilocularis evades host immune re...

Full description

Saved in:
Bibliographic Details
Main Authors: Xue Zhang, Liang Li, Tao Sun, Ning Yang, Hui Liu, Jin Chu, Junlong Xue, Guodong Lü, Tuerganaili Aji, Xiaojuan Bi, Renyong Lin
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Microbiology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmicb.2025.1624387/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849429188926242816
author Xue Zhang
Liang Li
Tao Sun
Ning Yang
Hui Liu
Jin Chu
Junlong Xue
Guodong Lü
Tuerganaili Aji
Xiaojuan Bi
Renyong Lin
Renyong Lin
author_facet Xue Zhang
Liang Li
Tao Sun
Ning Yang
Hui Liu
Jin Chu
Junlong Xue
Guodong Lü
Tuerganaili Aji
Xiaojuan Bi
Renyong Lin
Renyong Lin
author_sort Xue Zhang
collection DOAJ
description IntroductionAlveolar echinococcosis (AE) is a life-threatening zoonotic parasitic disease caused by the metacestode stage of Echinococcus multilocularis, characterized by granulomatous lesions and liver fibrosis. Immune exhaustion is the key mechanism by which E. multilocularis evades host immune responses and maintains long-term parasitism. Although CD155 is recognized as an immune checkpoint molecule, its specific role and underlying mechanism in AE remain unclear.MethodsA mouse model of E. multilocularis infection was used to investigate the role of CD155 in AE progression. Flow cytometry, immunohistochemistry, and immunofluorescence were employed to assess CD155 expression and analyze T-cell function. In addition, liver weight, lesion size, lesion number, inflammation index, collagen deposition (via Masson staining), and stellate cell activation (via α-SMA immunohistochemistry) were statistically quantified in the CD155 hepatocyte knockout mice. Each experimental group included five mice (n = 5).ResultsCD155 expression in hepatocytes was significantly increased—approximately 2-fold compared to Sham controls—and predominantly localized near lesion sites. The infected group showed significantly reduced percentages of functional CD4+IFN-γ+, CD4+CD107a+, and CD8+CD107a+ T cells (p < 0.05), along with enrichment of exhausted TIGIT+ T cells adjacent to CD155+ hepatocytes. In vitro, CD155 expression in hepatocytes was upregulated in a dose-dependent manner when co-cultured with metacestode vesicles, reaching 1.5-fold that of the control. Notably, hepatocyte-specific CD155 knockout in infected mice restored CD4+ and CD8+ T-cell function and reduced liver damage, as indicated by decreased lesion burden.ConclusionIn the E. multilocularis infection mouse model, excretory/secretory products from metacestode vesicles upregulated CD155 expression in hepatocytes, contributing to an immunosuppressive microenvironment and T-cell exhaustion. Targeting CD155 reverses this immunosuppression and mitigates hepatic pathology, highlighting CD155 as a promising therapeutic target for AE.
format Article
id doaj-art-778f7c6013e44fd296b54bfc95ee1fb0
institution Kabale University
issn 1664-302X
language English
publishDate 2025-07-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Microbiology
spelling doaj-art-778f7c6013e44fd296b54bfc95ee1fb02025-08-20T03:28:26ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2025-07-011610.3389/fmicb.2025.16243871624387CD155 as a therapeutic target in alveolar echinococcosis: insights from an Echinococcus multilocularis infection mouse modelXue Zhang0Liang Li1Tao Sun2Ning Yang3Hui Liu4Jin Chu5Junlong Xue6Guodong Lü7Tuerganaili Aji8Xiaojuan Bi9Renyong Lin10Renyong Lin11State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, ChinaXinjiang Key Laboratory of Echinococcosis, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, ChinaState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, ChinaState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, ChinaState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, ChinaState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, ChinaXinjiang Key Laboratory of Echinococcosis, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, ChinaState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, ChinaDepartment of Hepatobiliary and Hydatid Diseases, Digestive and Vascular Surgery Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, ChinaState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, ChinaState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, ChinaXinjiang Key Laboratory of Echinococcosis, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, ChinaIntroductionAlveolar echinococcosis (AE) is a life-threatening zoonotic parasitic disease caused by the metacestode stage of Echinococcus multilocularis, characterized by granulomatous lesions and liver fibrosis. Immune exhaustion is the key mechanism by which E. multilocularis evades host immune responses and maintains long-term parasitism. Although CD155 is recognized as an immune checkpoint molecule, its specific role and underlying mechanism in AE remain unclear.MethodsA mouse model of E. multilocularis infection was used to investigate the role of CD155 in AE progression. Flow cytometry, immunohistochemistry, and immunofluorescence were employed to assess CD155 expression and analyze T-cell function. In addition, liver weight, lesion size, lesion number, inflammation index, collagen deposition (via Masson staining), and stellate cell activation (via α-SMA immunohistochemistry) were statistically quantified in the CD155 hepatocyte knockout mice. Each experimental group included five mice (n = 5).ResultsCD155 expression in hepatocytes was significantly increased—approximately 2-fold compared to Sham controls—and predominantly localized near lesion sites. The infected group showed significantly reduced percentages of functional CD4+IFN-γ+, CD4+CD107a+, and CD8+CD107a+ T cells (p < 0.05), along with enrichment of exhausted TIGIT+ T cells adjacent to CD155+ hepatocytes. In vitro, CD155 expression in hepatocytes was upregulated in a dose-dependent manner when co-cultured with metacestode vesicles, reaching 1.5-fold that of the control. Notably, hepatocyte-specific CD155 knockout in infected mice restored CD4+ and CD8+ T-cell function and reduced liver damage, as indicated by decreased lesion burden.ConclusionIn the E. multilocularis infection mouse model, excretory/secretory products from metacestode vesicles upregulated CD155 expression in hepatocytes, contributing to an immunosuppressive microenvironment and T-cell exhaustion. Targeting CD155 reverses this immunosuppression and mitigates hepatic pathology, highlighting CD155 as a promising therapeutic target for AE.https://www.frontiersin.org/articles/10.3389/fmicb.2025.1624387/fullEchinococcus multilocularisCD155T-cell exhaustionalveolar echinococcosismetacestode vesicles
spellingShingle Xue Zhang
Liang Li
Tao Sun
Ning Yang
Hui Liu
Jin Chu
Junlong Xue
Guodong Lü
Tuerganaili Aji
Xiaojuan Bi
Renyong Lin
Renyong Lin
CD155 as a therapeutic target in alveolar echinococcosis: insights from an Echinococcus multilocularis infection mouse model
Frontiers in Microbiology
Echinococcus multilocularis
CD155
T-cell exhaustion
alveolar echinococcosis
metacestode vesicles
title CD155 as a therapeutic target in alveolar echinococcosis: insights from an Echinococcus multilocularis infection mouse model
title_full CD155 as a therapeutic target in alveolar echinococcosis: insights from an Echinococcus multilocularis infection mouse model
title_fullStr CD155 as a therapeutic target in alveolar echinococcosis: insights from an Echinococcus multilocularis infection mouse model
title_full_unstemmed CD155 as a therapeutic target in alveolar echinococcosis: insights from an Echinococcus multilocularis infection mouse model
title_short CD155 as a therapeutic target in alveolar echinococcosis: insights from an Echinococcus multilocularis infection mouse model
title_sort cd155 as a therapeutic target in alveolar echinococcosis insights from an echinococcus multilocularis infection mouse model
topic Echinococcus multilocularis
CD155
T-cell exhaustion
alveolar echinococcosis
metacestode vesicles
url https://www.frontiersin.org/articles/10.3389/fmicb.2025.1624387/full
work_keys_str_mv AT xuezhang cd155asatherapeutictargetinalveolarechinococcosisinsightsfromanechinococcusmultilocularisinfectionmousemodel
AT liangli cd155asatherapeutictargetinalveolarechinococcosisinsightsfromanechinococcusmultilocularisinfectionmousemodel
AT taosun cd155asatherapeutictargetinalveolarechinococcosisinsightsfromanechinococcusmultilocularisinfectionmousemodel
AT ningyang cd155asatherapeutictargetinalveolarechinococcosisinsightsfromanechinococcusmultilocularisinfectionmousemodel
AT huiliu cd155asatherapeutictargetinalveolarechinococcosisinsightsfromanechinococcusmultilocularisinfectionmousemodel
AT jinchu cd155asatherapeutictargetinalveolarechinococcosisinsightsfromanechinococcusmultilocularisinfectionmousemodel
AT junlongxue cd155asatherapeutictargetinalveolarechinococcosisinsightsfromanechinococcusmultilocularisinfectionmousemodel
AT guodonglu cd155asatherapeutictargetinalveolarechinococcosisinsightsfromanechinococcusmultilocularisinfectionmousemodel
AT tuerganailiaji cd155asatherapeutictargetinalveolarechinococcosisinsightsfromanechinococcusmultilocularisinfectionmousemodel
AT xiaojuanbi cd155asatherapeutictargetinalveolarechinococcosisinsightsfromanechinococcusmultilocularisinfectionmousemodel
AT renyonglin cd155asatherapeutictargetinalveolarechinococcosisinsightsfromanechinococcusmultilocularisinfectionmousemodel
AT renyonglin cd155asatherapeutictargetinalveolarechinococcosisinsightsfromanechinococcusmultilocularisinfectionmousemodel